Corundum Systems Biology Expands U.S. Presence with Appointment of Senior Executives

Addition of New Team Members will Bolster Venture Builder's Expertise in Microbiome R&D and Data Science

TOKYO, Feb. 25, 2025 /PRNewswire/ -- Corundum Systems Biology (CSB), a leading investment company dedicated to advancing life-changing systems biology solutions for human health and well-being, today announced the appointment of two senior executives. Former Takeda Pharmaceuticals Associate Scientific Director Henry Haiser, PhD joins as Operating Partner, and Rotem Gura-Sadovsky, PhD has been appointed Senior Director, Head of Data Strategy.

The appointment of doctors Haiser and Gura-Sadovsky strengthens CSB's capabilities to evaluate emerging technologies, optimize portfolio strategies, and accelerate the development of transformative health solutions. They bring extensive experience in biopharma innovation and specifically microbiome therapies. Their appointments will ensure CSB remains at the forefront of systems biology innovation, delivering measurable impact in the healthcare sector.

"The addition of Dr. Haiser and Dr. Gura-Sadovsky enhances our leadership team and highlights CSB's dedication to advancing novel health technologies," said Hidehiko Otake, CEO of Corundum Systems Biology. "Their expertise will accelerate our efforts to identify, invest in, and support US-based ventures focused on transformative solutions in systems biology."

Henry Haiser, PhD, joins CSB with over a decade of pharmaceutical drug discovery experience, having held leadership roles at Takeda Pharmaceuticals and Novartis. He played a pivotal role in establishing the microbiome discovery platform at Novartis Institutes for Biomedical Research, focused on identifying and characterizing bioactive small molecules produced by the gut microbiome, and has advanced programs from discovery to Phase 2 clinical trials. At CSB, Dr. Haiser will collaborate with the organization's portfolio companies, providing the scientific insights and strategic guidance essential to transition from a foundational platform to impactful solution.

"CSB plays a unique role in supporting researchers and innovators at the earliest stages of their development process, providing the long-term guidance and support essential for commercial success," said Dr. Haiser. "I'm looking forward to meeting with the minds behind the next generation of microbiome therapies and helping shape the future of the systems biology industry."

Rotem Gura-Sadovsky, PhD, brings expertise in systems biology, AI and machine learning, and big data analytics, with previous roles at Finch Therapeutics and Enveda Biosciences. At Enveda, he supported the discovery of natural products from medicinal plants and led a nascent platform utilizing multi-omics data to develop diagnostics. While at Finch Therapeutics he analyzed clinical and microbiome data to design live bacterial therapies.  Dr. Gura-Sadovsky will lead CSB's data science strategy.

"Joining CSB provides an exciting opportunity to work with scientists at the forefront of health innovation. I look forward to supporting researchers and entrepreneurs to develop new solutions and therapies in the field of microbiome and integrative-omics," said Dr. Gura-Sadovsky.

About Corundum Systems Biology

Corundum Systems Biology (CSB) is dedicated to advancing breakthroughs in human health and well-being by supporting groundbreaking companies in the field of systems biology. Committed to the long-term success and impact of its portfolio companies, Corundum Systems Biology offers deep domain expertise, connections to a broad network of industry and scientific leaders, and access to unique sources of health data. For company updates and information, follow Corundum Systems Biology on LinkedIn or visit https://www.csb.co.jp/.

Media Contact

Danny Sudwarts
FINN Partners for Corundum Systems Biology
[email protected]

SOURCE Corundum Systems Biology